Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
14-12-09	Merck : to take on superbugs with Cubist Pharma buy	RE
14-12-08	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
14-12-08	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
14-12-08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
14-12-05	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
13-05-20	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

15-01-13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
14-12-19	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
14-12-09	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
14-12-08	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
14-12-08	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

14-12-21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
14-12-20	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
14-12-09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
14-12-08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
14-12-08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	1996-12-31

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	2006-08-31
Kenneth J. Martin BRD	Director/Board Member	72	2013-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-1.87%	+4.22%	+44.36%	+1.14%	82.65B
CSL LIMITED	+0.56%	+2.30%	-17.74%	-34.56%	60.24B
MODERNA, INC.	-2.23%	+5.48%	+478.96%	+34.47%	58.11B
SAMSUNG BIOLOGICS CO.,LTD.	-2.03%	-2.62%	-8.63%	+29.27%	49.68B
UCB	-4.58%	-2.73%	+1.79%	+155.89%	46.66B
BIOGEN INC.	-1.64%	+1.07%	+56.98%	-16.26%	32.63B
INCYTE CORPORATION	-0.98%	+1.91%	+46.30%	+100.59%	25.69B
INNOVENT BIOLOGICS, INC.	-0.10%	-1.16%	+2.09%	+190.24%	22.73B
SWEDISH ORPHAN BIOVITRUM AB	-1.13%	-2.45%	+64.66%	+108.82%	16.54B
Average	-1.52%	-0.07%	+74.31%	+63.29%	43.88B
Weighted average by Cap.	-1.66%	+0.81%	+86.72%	+42.85%

Employees

Sector